These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32501943)

  • 21. Therapeutic approaches in patients with inflammatory myopathies.
    Dalakas MC
    Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current diagnosis and treatment of polymyositis and dermatomyositis.
    Sasaki H; Kohsaka H
    Mod Rheumatol; 2018 Nov; 28(6):913-921. PubMed ID: 29669460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corticosteroids in Myositis and Scleroderma.
    Postolova A; Chen JK; Chung L
    Rheum Dis Clin North Am; 2016 Feb; 42(1):103-18, ix. PubMed ID: 26611554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic strategy in inflammatory myopathies (polymyositis, dermatomyositis, overlap myositis, and immune-mediated necrotizing myopathy)].
    Tournadre A
    Rev Med Interne; 2014 Jul; 35(7):466-71. PubMed ID: 24144868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.
    Cherin P; Pelletier S; Teixeira A; Laforet P; Genereau T; Simon A; Maisonobe T; Eymard B; Herson S
    Arthritis Rheum; 2002 Feb; 46(2):467-74. PubMed ID: 11840450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
    Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
    Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis).
    Pongratz D
    J Neurol; 2006 Sep; 253 Suppl 5():V64-5. PubMed ID: 16998756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
    Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
    J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre.
    Loarce-Martos J; Lilleker JB; Parker M; McHugh N; Chinoy H
    Rheumatology (Oxford); 2021 Jul; 60(7):3398-3403. PubMed ID: 33367878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins].
    Chérin P; Herson S
    Ann Med Interne (Paris); 1993; 144(8):521-5. PubMed ID: 8179241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study.
    Egeli BH; Ergun S; Cetin A; Gursoy YK; Ugurlu S
    Clin Rheumatol; 2022 Jan; 41(1):123-127. PubMed ID: 34387760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dermatomyositis and polymyositis: clinical aspects and treatment].
    Hachulla E
    Ann Med Interne (Paris); 2001 Nov; 152(7):455-64. PubMed ID: 11965087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic advances in myositis.
    Aggarwal R; Oddis CV
    Curr Opin Rheumatol; 2012 Nov; 24(6):635-41. PubMed ID: 22955021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of Dermatomyositis and Immune-Mediated Necrotizing Myopathy with Poor Muscle Recovery with Steroids and IVIg: Therapeutic Strategies for Refractory Inflammatory Myositis].
    Tomimitsu H
    Brain Nerve; 2022 May; 74(5):545-552. PubMed ID: 35589645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
    Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
    Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inflammatory muscle diseases].
    Pongratz D
    Z Rheumatol; 1986; 45(4):133-8. PubMed ID: 3776360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic strategies in idiopatic inflammatory myopathies].
    Chakour R; Leimgruber A; Bart PA; Spertini F
    Rev Med Suisse; 2009 Apr; 5(199):812-8. PubMed ID: 19441746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of idiopathic inflammatory myopathies.
    Amato AA; Griggs RC
    Curr Opin Neurol; 2003 Oct; 16(5):569-75. PubMed ID: 14501840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.
    Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E
    Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Polymyositis/dermatomyositis--clinical picture and treatment].
    Anić B; Cerovec M
    Reumatizam; 2012; 59(2):44-50. PubMed ID: 23745455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.